Rebound phenomena in manic patients following physostigmine. Preliminary observations

Neuropsychobiology
B ShopsinS Gershon

Abstract

The authors have administered physostigmine intravenously to three hospitalized manic patients on a double-blind basis. All three individuals showed clinical change both during and after the physostigmine period, which can be clearly delineated into three distinct phases. The behavioral modifications occurring during the physostigmine run did not qualitatively alter the underlying mania. The authors focus on 'rebound' phenomena, or post-physostigmine changes, as a possible clinical index with which chemically to characterize the initial state of amine imbalance responsible for a given affective illness. The data are considered consistent with an adrenergic-dopaminergic-cholinergic balance hypothesis of affective disorders, and may provide a relevant link in understanding the interface or crossover between manic and schizo-affective illness.

Citations

Sep 1, 1986·Brain Research·S C Dilsaver
Jan 1, 1983·Progress in Neuro-psychopharmacology & Biological Psychiatry·D S JanowskyJ C Gillin
Dec 15, 1994·American Journal of Medical Genetics·D S JanowskyJ I Nurnberger
Oct 1, 1984·Acta Psychiatrica Scandinavica·M HaagW Greil
Aug 15, 2020·Cognitive, Affective & Behavioral Neuroscience·Zackary A CopeJared W Young

Related Concepts

Manic Disorder
Clinical Trials
Eserine
Neurosteroids

Related Feeds

Bipolar Disorder

Bipolar disorder is characterized by manic and/or depressive episodes and associated with uncommon shifts in mood, activity levels, and energy. Discover the latest research this illness here.

© 2021 Meta ULC. All rights reserved